HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John C Byrd Selected Research

apolizumab

12/2009A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
3/2004Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John C Byrd Research Topics

Disease

226B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
11/2022 - 02/2002
172Neoplasms (Cancer)
01/2022 - 02/2002
61Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022 - 01/2004
50Leukemia
11/2021 - 02/2002
32Lymphoma (Lymphomas)
01/2021 - 04/2003
22Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2022 - 02/2002
21Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
01/2021 - 01/2009
20Disease Progression
01/2022 - 01/2002
18Hematologic Neoplasms (Hematological Malignancy)
01/2021 - 09/2003
15Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2022 - 04/2007
14Tumor Lysis Syndrome
10/2020 - 08/2003
13Infections
11/2021 - 04/2002
13Multiple Myeloma
01/2019 - 05/2008
11Chromosome Aberrations (Chromosome Abnormalities)
01/2022 - 01/2003
11B-Cell Lymphoma (Lymphoma, B Cell)
01/2021 - 08/2003
10Diarrhea
01/2021 - 07/2010
9Myelodysplastic Syndromes (Myelodysplastic Syndrome)
12/2020 - 04/2008
8Atrial Fibrillation
11/2021 - 03/2015
8Hemorrhage
01/2021 - 01/2015
8Fatigue
12/2019 - 09/2011
8Breast Neoplasms (Breast Cancer)
01/2018 - 01/2013
8BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
12/2014 - 05/2005
7Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
12/2021 - 03/2009
7Neutropenia
01/2020 - 07/2010
7Lymphocytosis
01/2020 - 09/2006
7Lymphoproliferative Disorders (Lymphoproliferative Disorder)
05/2016 - 04/2008
6Hypertension (High Blood Pressure)
01/2022 - 12/2018
6Lymphadenopathy
11/2019 - 09/2006
5Nausea
12/2019 - 01/2003
5Residual Neoplasm
12/2016 - 03/2004
5Thrombocytopenia (Thrombopenia)
01/2015 - 04/2005
4B-Cell Leukemia (Leukemia, B Cell)
01/2021 - 10/2007
4Cytopenia
01/2020 - 02/2014
4Lymphoid Leukemia
04/2017 - 01/2004
4Graft vs Host Disease (Graft-Versus-Host Disease)
12/2016 - 04/2005
4Agammaglobulinemia (Hypogammaglobulinemia)
01/2016 - 04/2002
4Fever (Fevers)
07/2014 - 09/2002
4Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
11/2013 - 02/2004

Drug/Important Bio-Agent (IBA)

82ibrutinibIBA
11/2022 - 06/2011
42Agammaglobulinaemia Tyrosine KinaseIBA
01/2022 - 06/2011
42Rituximab (Mabthera)FDA Link
01/2020 - 02/2002
36Proteins (Proteins, Gene)FDA Link
11/2021 - 01/2003
28alvocidib (flavopiridol)IBA
06/2016 - 06/2005
27fludarabineIBA
05/2015 - 02/2002
22Pharmaceutical PreparationsIBA
01/2021 - 04/2005
19Biological ProductsIBA
01/2020 - 01/2002
18Lenalidomide (CC 5013)FDA Link
12/2020 - 05/2008
17acalabrutinibIBA
01/2022 - 01/2016
16Monoclonal AntibodiesIBA
01/2020 - 02/2002
12Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2020 - 12/2005
11MicroRNAs (MicroRNA)IBA
01/2018 - 06/2009
11Histones (Histone)IBA
01/2016 - 07/2003
10DecitabineFDA Link
01/2020 - 07/2005
10Cyclin-Dependent Kinases (cdk Proteins)IBA
04/2016 - 01/2007
10DNA (Deoxyribonucleic Acid)IBA
01/2016 - 02/2005
9Cytarabine (Cytosar-U)FDA LinkGeneric
12/2020 - 01/2003
9Phosphotransferases (Kinase)IBA
01/2020 - 05/2005
9Bortezomib (Velcade)FDA Link
01/2020 - 09/2006
9Immunoglobulins (Immunoglobulin)IBA
04/2016 - 02/2004
9Fingolimod Hydrochloride (FTY720)FDA Link
09/2015 - 09/2007
8AntibodiesIBA
10/2022 - 08/2007
8venetoclaxIBA
12/2021 - 10/2018
8idelalisibIBA
11/2019 - 09/2010
8CytokinesIBA
01/2019 - 02/2011
8Pentostatin (Nipent)FDA LinkGeneric
01/2015 - 04/2005
8Alemtuzumab (Campath)FDA Link
12/2013 - 07/2003
7obinutuzumabIBA
01/2022 - 01/2016
7Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA
11/2021 - 08/2004
7AntigensIBA
12/2016 - 03/2004
7Interleukin-2 (IL2)IBA
12/2016 - 09/2004
6RNA (Ribonucleic Acid)IBA
10/2020 - 06/2009
6interleukin-21 (interleukin 21)IBA
01/2020 - 05/2008
6Imatinib Mesylate (Gleevec)FDA Link
12/2014 - 05/2005
5OSU-2SIBA
01/2022 - 06/2011
5Histone Deacetylases (Histone Deacetylase)IBA
01/2021 - 07/2003
5Biomarkers (Surrogate Marker)IBA
01/2019 - 12/2007
5ofatumumabFDA Link
12/2018 - 03/2013
5Histone Deacetylase InhibitorsIBA
10/2017 - 01/2004
5Messenger RNA (mRNA)IBA
04/2017 - 08/2007
5milatuzumabIBA
06/2015 - 04/2011
5MethyltransferasesIBA
06/2009 - 02/2005
4Chlorambucil (Leukeran)FDA Link
01/2022 - 05/2006
4Long Noncoding RNAIBA
01/2022 - 12/2014
4EnzymesIBA
01/2021 - 04/2004
4mouse MIRN29 microRNAIBA
01/2019 - 06/2009
4Immunoglobulin G (IgG)IBA
04/2016 - 02/2004
4OligodeoxyribonucleotidesIBA
06/2015 - 04/2008
4Antisense OligonucleotidesIBA
06/2015 - 01/2003
4OligonucleotidesIBA
01/2013 - 06/2009
4NF-kappa B (NF-kB)IBA
07/2010 - 02/2008
4Complement System Proteins (Complement)IBA
01/2008 - 02/2002
4CaspasesIBA
03/2005 - 02/2002
3Chimeric Antigen ReceptorsIBA
11/2022 - 03/2016
3selinexorIBA
01/2022 - 05/2015

Therapy/Procedure

145Therapeutics
10/2022 - 04/2002
35Drug Therapy (Chemotherapy)
01/2022 - 02/2002
6Immunotherapy
01/2022 - 09/2004
5Aftercare (After-Treatment)
01/2019 - 02/2002
5Renal Dialysis (Hemodialysis)
05/2015 - 11/2007
4Stem Cell Transplantation
01/2020 - 01/2006